The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs UB 421 (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Proof of concept
- Sponsors United BioPharma
- 21 Nov 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Aug 2019 to 1 Aug 2020.
- 20 Jun 2019 Status changed from not yet recruiting to recruiting.
- 01 Apr 2019 Planned End Date changed from 1 Jul 2020 to 1 Dec 2020.